Home » Teva Acquires Japan’s Taiyo for $934 Million

Teva Acquires Japan’s Taiyo for $934 Million

July 14, 2011

Teva Pharmaceutical completed its purchase of Taiyo Pharmaceutical, laying out $934 million in cash. Taiyo is Japan’s third largest generic drugs manufacturer; it reported $530 million in sales last year.
Israel Diamond Portal

10Mar
FDA Drug GMP Facility Inspections During the Pandemic
16Mar
Pharmaceutical Naming Regulation: Understanding the Latest Developments
18Mar
Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
30Mar
Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges
06Apr
Medical Device Cybersecurity: Understand the Latest Developments

Teva Acquires Japan’s Taiyo for $934 Million

Upcoming Events

FDA Drug GMP Facility Inspections During the Pandemic

Pharmaceutical Naming Regulation: Understanding the Latest Developments

Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Abbott Gets FDA EUA for COVID-19 IgG Antibody Test

In $1.55 Billion Deal, Perrigo Sells Off Generic Drug Business

Turkish Researchers Downgrade Sinovac’s COVID-19 Vaccine Efficacy Rate

Luminex Receives EUA for Expanded Respiratory Pathogen Panel, Clearing It for COVID-19

The Revised ICH E8: A Guide to New Clinical Trial Requirements